IR RELEASE Q1 2009



ALAPIS S.A.

Greece, Health, Pharmaceuticals

May 27, 2009

Company Description

Alapis Group is primarily active in 2 major strategic business units:

I. Healthcare: Pharmaceuticals, Medical Devices & Equipment,

Veterinary Pharmaceuticals and

II. Non-Healthcare: Cosmetics

and Detergents.

Share Data

Price (€) 25/05/2009	0.87
# of shares (M.)	980.6
Capitalization (M €)	853.1
ATHEX	ALAPIS
REUTERS	ALAr.AT
BLOOMBERG	ALAPIS_GA
ISIN	GRS 322003013

Key Figures & Ratios

P&L HIGHLIGHTS		FY 2007	FY 2008*	
SALES	(000 €)	442,487	1,136,285	
EBITDA	(000 €)	117,417	277,926	
EATAM	(000 €)	81,276	146,691	
RATIOS		FY 2007	FY 2008*	
P/E	(x)	10.50	5.82	
P/BV	(x)	0.53	0.55	
EV/EBITDA	(x)	5.34	5.46	

(*) Results excluding the impairment of goodwill amounting € 94.6 mil.

Investment ratios computed at share price 0.87 (25/05/2009) and no. of shares 980,600,220.

Key Developments

- Q1 2009 consolidated turnover amounted to EUR 235.6 mil. (+13.2% over Q1 2008), mainly due to the consolidation of PNG Gerolymatos Group.
- · Consolidated EBITDA: EUR 75.8 mil. (+31.5% over Q1 2008), as a result of the increasing contribution of the health sector to the consolidated results
- EBITDA margin stood at 32.2% of consolidated sales over 27.7% in Q1 2008
- Consolidated EATAM: EUR 31.4 mil. (-2.8%), due to the loss making discontinued sector of organic products
- Consolidated EATAM from continued operations: EUR 34.1 mil. (+8.5%)

Health sector (Human and Veterinary)

- Health sector turnover: EUR 210.6 mil. (+24.6%)
- Health sector EBITDA: EUR 74.9 mil. (+59.2%)
- Growth posted due to:
 - 1. The consolidation of PNG Gerolymatos Group,
 - 2. The increasing contribution of the generics products in the consolidated sales.

Other activities (Cosmetics and Detergents)

- Segment's turnover: EUR 21 mil (-40.8%)
- Segment's EBITDA: EUR 3.6 mil. (-60.8%)
- Detergent and cosmetics sector's reduced activity is attributed to the global financial crisis which has a severe impact in this sector.

Discontinued operation (Organic products)

- · Organic products' segment EBITDA: losses of EUR 2.73 mil (vs earnings of EUR 1.3 mil.)
- Segment's EATAM: losses of EUR 2.68 mil. (vs earnings of EUR 889 th.)
 Due to the significant reduction in the performance of the organic products division, the termination of the operation of the said division and the commencement of the liquidation process of the companies that are active in this sector was decided.

Resent Corporate Developments

- Business development
 - 1. During 1st Quarter 2009 we have successfully launched generic products in CNS (6), CVS (7) and Oncology (4).
 - 2. In addition, five new contracts with multinational companies have been signed, thus giving the company 35 to 40 new products within the next 24 months.
 - As a result of the companies' decision to invest into R&D facilities starting in 2008 with the aim to develop own dossiers - five contracts for product outlicensing have been already signed by the Group in the 1st Quarter 2009, covering 7 products for European countries.
- Group integration
 - 1. Several departments have started to consolidate and integrate such as Finance, HR, Medical and Registration.
 - 2. Production facilities have been upgraded in order to accommodate the production of generic products in our own facilities


Q1 Financial Results

(FY: December) (M €)	Q1 2008	Q1 2009	Δ (%)	Q1 2008*	Q1 2009*	Δ (%)
Sales Gross Profit EBITDA EBIT EBT EAT & Minorities	208.1 64.7 57.7 41.7 39.0 32.3	82.1 75.8 50.3 36.9	13.2% 26.9% 31.5% 20.5% -5.6% -2.8%	204.4 63.3 56.4 40.9 38.2 31.4	82.5 78.6	13.3% 30.4% 39.3% 31.7% 5.8% 8.5%
Margin Analysis %	Q1 2008	Q1 2009		Q1 2008*	Q1 2009*	
Gross Profit EBITDA EBIT EBT EAT & Minorities	31.1% 27.7% 20.1% 18.8% 15.5%	34.9% 32.2% 21.4% 15.6% 13.3%		31.0% 27.6% 20.0% 18.7% 15.4%	35.6% 33.9% 23.2% 17.4% 14.7%	

Reclassifications have been made in 2008 figures due to the finalization of the goodwill of the merger *Results from continued operations (excluding the discontinued operation of organic products)

Contacts: ALAPIS S.A., 2 Aftokratoros Nikolaou st., Athens, 17671, Greece, Tel:+30 213 0175051, www.alapis.eu CFO: Vasilis Karamouzis +30213 0175050 v.karamouzis@alapis.eu

Consolidated Income Statement Q1 2007 Q1 2008 Q1 2008* Q1 2009 Q1 2009* 204 387 235 576 49 511 208 091 231 553 -141,084 -153,438 -31,301 -143,371 **Gross Profit** 18,210 64,720 63,303 82,138 82.517 3,510 Other Revenues-(Expenses) 472 3,558 1.631 1.575 SG&A Expenses -8.169 -26,531 -25.955 -33,458 -30,263 EBITDA 12,523 57.667 56,381 75,824 78,555 -2,009 -15,920 -15,523 Depreciation -25,513 -24,726 10.514 50.311 EBIT 41,747 40,858 53.829 **Total Financial Results** -1.194 -2,708 -2,705 -13,458 -13,452 9,319 39,039 38,153 36,852 40,377 -5,743 -6,588 Taxation -1,920 -6,800 -6,803 Minorities -66 -304 -304 EAT & Minorities 7.399 32,304 31.416 31.414 34.093 Margin Analysis % Q1 2007 Q1 2008 Q1 2008* Q1 2009 Q1 2009* **Gross Profit** 36.8% 31.1% 31.0% 34.9% 35.6% SG&A Expenses 16.5% 12.7% 12.7% 14.2% 13.1% 27.6% EBITDA 25.3% 27.7% 32.2% 33.9% 21.2% 20.1% 20.0% 21.4% 23.2% 18.8% 18.7% 15.6% 17.4% 18.8% EBT **EAT & Minorities** 14.9% 15.5% 15.4% 13.3% 14.7% Period / Period % Q1 2007 Q1 2008 Q1 2008* Q1 2009 Q1 2009* 320.3% 13.2% 13.3% **Gross Profit** 255.4% 26.9% 30.4% SG&A Expenses 224.8% 26.1% 16.6% EBITDA 360.5% 31.5% 39.3% EBIT 297.1% 20.5% 31.7% -5.6% 318.9% 5.8% EBT **EAT & Minorities** 336.6% -2.8% 8.5% Reclassifications have been made in 2008 figures due to the finalization of the goodwill of the merger *Results from continued operations (excluding the discontinued operation of organic products)




98.8%

Healthcare

Consolidated Statement of Financial Position (in 000, €) FY 2007 FY 2008 Q1 2009 ASSETS Non-current Assets Tangible Assets 529,211 1,525,032 730,186 1,004 Intangible Assets 759,489 716.037 18,925 Other long-term assets 1,100 Deferred income taxes Total Non-Current Assets 15,341 **2,348,312** 15,390 **2,271,612** 1,319,397 **Current Assets** 119,499 149,801 174,480 Inventories 15,535 62,084 75,022 127,059 106,409 109,527 Trade accounts receivables Other current assets Cash and Cash equivalents Total Current Assets 318.023 208,679 95,561 515,141 560,561 485,977 2,832,173 2,881,820 TOTAL ASSETS **EQUITY & LIABILITIES** 294 180 294 180 294 180 Paid-in surplus Adjustment's differences and other reserves 92,986 103,217 103,103 Merger reserve Own shares reserve -95.616 -95.616 Retained earnings 44,393 58,590 16,851 Minority interests Total Equity 152 **1,497,967** 1,543,001 1,609,056 Non-Current Liabilities Long-term borrowings at amortised cost Deffered Tax Liabilities 62 052 702 606 737 763 Provisions for dismissal indemnities 4.196 8.582 8,844 Other long-term Liabili **Total Non-Current Liabilities** 108,662 825,395 860,499 **Current Liabilities** Trade accounts payable Short-term borrowings 29,570 169,459 150.013 Income taxes payable 17,413 33.531 16,345 19,987 Accrued and other current liabilities 104 758 92 738 Total Current Liabilities TOTAL LIABILITIES & EQUITY 463,777 2,832,173 Reclassifications have been made in 2007 and 2008 figures due to the finalization

of the goodwill of the merger



This presentation contain forward-looking statements. These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Group. They are not historical facts, nor are they guarantees of future performance. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Further details of potential risks and uncertainties affecting ALAPIS Group are described in the ALAPIS's filings with the Athens Stock Exchange. These forward-looking statements speak only as of the date of this presentation.